Laurus Labs Ltd
Laurus Labs Ltd (LAURUSLABS) last reported results for the quarter ended Jun 2026, with sales of ₹2,026 crore and net profit of ₹362 crore. The stock last traded at ₹2,013, a market capitalisation of ₹1,08,746 crore, on a P/E of 99.5. Over the past 52 weeks the stock has ranged between ₹843 and ₹2,055. Figures are as of 6 Oct 2026 and are not real time.
Laurus Labs Ltd share price and key metrics
- Current price
- ₹2,013
- Market cap
- ₹1,08,746 cr
- Stock P/E
- 99.5
- Book value
- ₹98.2
- ROE
- 18.3%
- ROCE
- 17.8%
- Dividend yield
- 0.10%
- 52w high / low
- 2055/843
Metrics as of 6 Oct 2026. Not real time.
Track Laurus Labs Ltd
Cruxal reads every Laurus Labs Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Laurus Labs Ltd growth and returns
- 10 Years
- 14%
- 5 Years
- 7%
- 3 Years
- 4%
- TTM
- 23%
- 10 Years
- 21%
- 5 Years
- -2%
- 3 Years
- 4%
- TTM
- 115%
- 10 Years
- %
- 5 Years
- 25%
- 3 Years
- 70%
- 1 Year
- 128%
- 10 Years
- 17%
- 5 Years
- 15%
- 3 Years
- 10%
- Last Year
- 18%
Laurus Labs Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹2,026 cr, up 29.0% from ₹1,570 cr a year earlier. Net profit was ₹362 cr, up 123.5% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 1,224 | 1,415 | 1,720 | 1,570 | 1,653 | 1,778 | 1,812 | 2,026 |
| Expenses | 1,045 | 1,130 | 1,300 | 1,187 | 1,250 | 1,298 | 1,299 | 1,388 |
| Operating profit | 178 | 285 | 421 | 382 | 403 | 480 | 512 | 638 |
| OPM % | 15% | 20% | 24% | 24% | 24% | 27% | 28% | 32% |
| Other income | 5 | 9 | 59 | 10 | 27 | 6 | 12 | 9 |
| Interest | 53 | 58 | 56 | 52 | 40 | 39 | 40 | 42 |
| Depreciation | 108 | 106 | 110 | 117 | 120 | 121 | 122 | 124 |
| Profit before tax | 23 | 131 | 312 | 224 | 270 | 327 | 361 | 481 |
| Tax % | 22% | 31% | 25% | 28% | 28% | 22% | 22% | 25% |
| Net profit | 20 | 93 | 233 | 162 | 194 | 252 | 282 | 362 |
| EPS (₹) | 0.37 | 1.71 | 4.33 | 3.02 | 3.61 | 4.66 | 5.17 | 6.80 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Laurus Labs Ltd annual results
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,905 | 2,056 | 2,292 | 2,832 | 4,814 | 4,936 | 6,041 | 5,041 | 5,554 | 6,813 | 7,270 |
| Operating profit | 408 | 414 | 357 | 565 | 1,552 | 1,424 | 1,592 | 779 | 1,055 | 1,785 | 2,034 |
| OPM % | 21% | 20% | 16% | 20% | 32% | 29% | 26% | 15% | 19% | 26% | 28% |
| Net profit | 190 | 168 | 94 | 255 | 984 | 832 | 793 | 162 | 358 | 890 | 1,091 |
| EPS (₹) | 3.60 | 3.16 | 1.76 | 4.77 | 18.33 | 15.40 | 14.67 | 2.98 | 6.64 | 16.46 | 20.24 |
TTM is the trailing twelve months to the most recent quarter.
Laurus Labs Ltd balance sheet
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 106 | 106 | 106 | 107 | 107 | 107 | 108 | 108 | 108 | 108 |
| Reserves | 1,225 | 1,377 | 1,452 | 1,663 | 2,490 | 3,244 | 3,930 | 4,003 | 4,365 | 5,192 |
| Borrowings | 842 | 980 | 1,036 | 1,079 | 1,482 | 1,777 | 2,015 | 2,577 | 2,764 | 2,518 |
| Other liabilities | 481 | 554 | 737 | 901 | 1,671 | 1,840 | 1,608 | 1,699 | 2,099 | 2,693 |
| Total liabilities | 2,653 | 3,017 | 3,331 | 3,750 | 5,751 | 6,968 | 7,660 | 8,387 | 9,336 | 10,511 |
| Fixed assets | 1,230 | 1,481 | 1,629 | 1,726 | 2,171 | 2,652 | 3,409 | 3,890 | 4,123 | 4,371 |
| CWIP | 143 | 163 | 110 | 67 | 362 | 813 | 551 | 423 | 458 | 773 |
| Investments | 3 | 3 | 3 | 3 | 3 | 31 | 50 | 124 | 233 | 309 |
| Other assets | 1,277 | 1,369 | 1,589 | 1,953 | 3,214 | 3,472 | 3,651 | 3,950 | 4,521 | 5,058 |
| Total assets | 2,653 | 3,017 | 3,331 | 3,750 | 5,751 | 6,968 | 7,660 | 8,387 | 9,336 | 10,511 |
As reported by the company. Total assets equal total liabilities by construction.
Laurus Labs Ltd cash flow
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 332 | 342 | 298 | 347 | 733 | 911 | 994 | 666 | 602 | 1,624 |
| Cash from investing | -289 | -384 | -253 | -221 | -941 | -914 | -997 | -822 | -680 | -1,086 |
| Cash from financing | -54 | 42 | -45 | -128 | 255 | 30 | -27 | 250 | 39 | -525 |
| Net cash flow | -10 | 1 | -0 | -1 | 47 | 27 | -30 | 93 | -39 | 13 |
| Free cash flow | 55 | -49 | 44 | 125 | 49 | 34 | 6 | -10 | 61 | 560 |
| CFO / operating profit | 94% | 98% | 91% | 68% | 62% | 77% | 80% | 99% | 70% | 107% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Laurus Labs Ltd operating ratios
| Per year | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % | 16% | 14% | 8% | 14% | 40% | 26% | 23% | 7% | 9% | 18% |
| Debtor days | 109 | 101 | 113 | 102 | 99 | 100 | 96 | 120 | 132 | 115 |
| Inventory days | 186 | 201 | 201 | 234 | 266 | 293 | 222 | 277 | 285 | 317 |
| Days payable | 96 | 107 | 144 | 159 | 199 | 146 | 94 | 158 | 141 | 170 |
| Cash conversion cycle | 199 | 195 | 170 | 177 | 166 | 247 | 224 | 240 | 276 | 263 |
| Working capital days | 3 | -11 | 6 | 15 | 43 | 43 | 59 | 42 | 43 | 58 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Laurus Labs Ltd shareholding pattern
Promoters held 27.47% at Jun 2026, broadly unchanged since Jun 2025. FIIs 28.00% and DIIs 13.73%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 27.18% | 27.62% | 27.62% | 27.60% | 27.60% | 27.49% | 27.49% | 27.47% |
| FIIs | 26.08% | 25.56% | 25.51% | 25.70% | 26.17% | 26.52% | 25.82% | 28.00% |
| DIIs | 13.05% | 12.74% | 11.78% | 11.94% | 11.72% | 12.42% | 13.96% | 13.73% |
| Public | 33.69% | 34.09% | 35.09% | 34.78% | 34.52% | 33.57% | 32.73% | 30.79% |
| No. of shareholders | 3,09,063 | 2,92,214 | 2,92,905 | 2,80,223 | 2,83,678 | 2,80,756 | 2,92,281 | 2,91,653 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Cruxal coverage of Laurus Labs Ltd
Laurus Labs Ltd corporate filings
- Please see annexed enclosure.Company Updatelow impact
- Laurus Labs invests INR 12.10 crore in Kurnool Renewables Private Limited via rights issue, acquiring 1.21 crore shares at face value of INR 10 each, maintaining a 26% stakeCompany Updatehigh impact
Cruxal's analysis: Laurus Labs has further increased its stake in Kurnool Renewables Private Limited by…
Read the full analysis - Please see annexed enclosure.Insider Trading / SASTlow impact
- Laurus Labs Reports Strong 1Q FY27 Results with 29% Revenue Growth and 126% Net Profit SurgeCompany Updatehigh impact
Cruxal's analysis: Laurus Labs Limited has delivered a robust performance for 1Q FY27, reporting revenue of…
Read the full analysis - Laurus Labs Ltd schedules analyst/investor meetingCompany Updatelow impact
Cruxal's analysis: Laurus Labs has issued an intimation regarding an upcoming analyst/investor meeting. The…
Read the full analysis - Laurus Labs Ltd schedules analyst/investor meetingCompany Updatelow impact
Cruxal's analysis: Laurus Labs has issued an intimation regarding an upcoming analyst/investor meeting. The…
Read the full analysis - Laurus Labs Ltd schedules analyst/investor meetingCompany Updatelow impact
Cruxal's analysis: Laurus Labs has issued a routine intimation regarding an upcoming analyst/investor…
Read the full analysis - Laurus Labs Ltd announces intimation of analyst/investor meetingCompany Updatelow impact
Cruxal's analysis: Laurus Labs has filed a routine intimation regarding an upcoming analyst or investor…
Read the full analysis - Laurus Labs Ltd receives ESG score from NSE Sustainability Ratings and Analytics LimitedCompany Updatelow impact
Cruxal's analysis: Laurus Labs has submitted an intimation regarding the receipt of an ESG score from NSE…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.